Pharmaceuticals

A new grant funds a radical approach using AI and postmortem human brains to find crucial clues for Parkinson's therapies, aiming to crack a major medical challenge.

With promising brain scan data, a deep therapeutic pipeline, and a cash runway into 2027, Radiopharm Theranostics is gaining significant momentum.

Stoke Therapeutics' major new lease in Waltham signals a pivotal shift to commercialization and defies a cooling life sciences real estate market.

Undercover footage shows disturbing treatment of beagles at a Toronto lab, sparking calls for investigation and questioning Canada's animal research laws.

Top scientists, survivors, and industry leaders are uniting to accelerate a new generation of cancer vaccines, moving them from lab to patient faster than ever.

As it turns 60, Melmark adds two powerhouse leaders with deep personal ties to its mission, signaling a new era of strategic growth and innovation.

A new AI tool promises to cut SOP updates from days to hours, but how does it stack up in the race to automate regulatory compliance for drug makers?

Omeros begins sales of YARTEMLEA, the first and only approved therapy for TA-TMA, a fatal complication of stem cell transplants, shifting the paradigm.

Amid federal funding threats, state leaders and industry forge a strategic alliance to protect Connecticut’s $7B life sciences sector and fuel innovation.

With the appointment of Kelly Johnston McKee, Science 37 signals a major push to redefine patient experience and operationalize the future of clinical research.

BioTalent Canada's latest awards highlight how inclusivity, diversity, and equity are becoming key drivers of innovation and profit in the bioscience sector.

Veteran leader Emma Rooth takes charge at PCCA UK, bringing a track record of transformation to the booming personalized medicine market.

Roche's CT-388 posts impressive Phase II results, positioning it as a powerful new rival to Zepbound and Wegovy in the booming obesity drug market.

A strategic investment from Krieger Capital will fuel Global Key Solutions' AI platform, which transforms complex regulatory data into actionable safety insights.

A new study reveals albumin, the most abundant protein in blood, is a powerful weapon against mucormycosis, offering new hope for treating this fatal infection.

The acquisition strengthens the independent distributor's hold on the booming plasma therapy market, promising wider access to critical, complex medications.

New study shows oral weight loss drug QSYMIA, paired with digital tech, delivers major results, offering a cheaper alternative to pricey injectables.

A new COVID-19 drug targets patients who can't take Paxlovid, while a once-a-month pill could revolutionize how we prevent seasonal influenza.

With new VP of Sales David Florez, Peer AI aims to accelerate its mission of transforming regulatory documentation as the pharma industry moves beyond AI pilots.

Leios Therapeutics partners with BNC Korea, securing a key investment and pathway to Asia's lucrative body contouring market for its 10XB-101 injectable.